Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy
- DOI
- 10.1016/j.annonc.2023.05.006
- Published
- 2023-08
- Container
- Annals of Oncology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.annonc.2023.05.006,
title = {Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy},
author = {I.F. Tannock and G. Bouche and D.A. Goldstein and Y. Goto and A.S. Lichter and K. Prabhash and P. Ranganathan and L.B. Saltz and G.S. Sonke and G.W. Strohbehn and R. von Moos and M.J. Ratain},
year = {2023},
journal = {Annals of Oncology},
doi = {10.1016/j.annonc.2023.05.006},
url = {https://doi.org/10.1016/j.annonc.2023.05.006}
}RIS
TY - JOUR TI - Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy AU - I.F. Tannock AU - G. Bouche AU - D.A. Goldstein AU - Y. Goto AU - A.S. Lichter AU - K. Prabhash AU - P. Ranganathan AU - L.B. Saltz AU - G.S. Sonke AU - G.W. Strohbehn AU - R. von Moos AU - M.J. Ratain PY - 2023 JO - Annals of Oncology DO - 10.1016/j.annonc.2023.05.006 UR - https://doi.org/10.1016/j.annonc.2023.05.006 ER -
APA
Tannock, I., Bouche, G., Goldstein, D., Goto, Y., Lichter, A., Prabhash, K., Ranganathan, P., Saltz, L., Sonke, G., Strohbehn, G., Moos, R. V., & Ratain, M. (2023). Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy. Annals of Oncology. https://doi.org/10.1016/j.annonc.2023.05.006
Source records
- crossref · retrieved 2026-09-27T02:04:45.227Z